Pharmafile Logo

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. Last year the FDA approved 48 drugs in rare diseases, including both novel and repurposed drugs.

Rare diseases are attractive to pharma for a number of reasons. Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced regulatory fees, tax incentives and line extensions. Secondly, although patient populations for each disease in every market are small, if the drug gains approval across a number of indications, the manufacturer can increase its potential revenue. Thirdly, if successful, manufacturers have the opportunity to be a market leader in a niche area.

Find out more:
www.researchpartnership.com/news/2016/01/pharma-market-research-report-predictions-for-2016/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Rare diseases and orphan drugs: Our experience and expertise

We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the growing area of rare diseases and orphan drugs, which includes links to...

Conducting research for publication video

APAC Director Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their real value to patients, healthcare and society.Watch the video: https://bit.ly/2OcOWNu

Conference research case study

How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event

Portfolio analysis: Using market research to master communications across a therapeutic category

Many of us are familiar with billiard games, where two players compete to be the first to pocket all the balls on the table in a particular order.  We recently...

EphMRA round up 2018

EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.

Patients’willingness to pay

Considerations when developing an appropriate pricing strategy in self-pay markets

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...

Shift to preventative healthcare – Opportunities for screening, diagnostics and vaccination

Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...

Conference Live for ongoing congress performance measurement

Director John Branston discusses the benefits of a mobile approach for evaluating medical conferences year-on-year